Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model

Cancer Letters

Volumn 288, Issue 2, 2010, Pages 251-260

  Kim, Chung Kwon ^a   Joe, Young Ae ^a   Lee, Suk Keun ^b   Kim, Eun Kyoung ^a   O, Eunju ^a   Kim, Hyun Kyung ^a   Oh, Bae Jun ^a   Hong, Sung Hee ^c   Hong, Yong Kil ^a  

^a The Catholic University of Korea   (South Korea)

^b Gangneung Wonju National University   (South Korea)

^c Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

Angiogenesis; Celecoxib; Combination therapy; Glioma; Urokinase kringle

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; CELECOXIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RECOMBINANT PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE TYPE PLASMINOGEN ACTIVATOR 1; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MIGRATION INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; GLIOMA; HUMANS; KRINGLES; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; PYRAZOLES; RECOMBINANT PROTEINS; SULFONAMIDES; TIME FACTORS; TUMOR BURDEN; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 74849105917     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.07.008     Document Type: Article

References (42)

1. Kornblith P.K., Welch W.C., and Bradley M.K. The future of therapy for glioblastoma. Surg. Neurol. 39 (1993) 538-543
2. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 (2002) 1011-1018
3. Furnari F.B., Huang H.J., and Cavenee W.K. Genetics and malignant progression of human brain tumours. Cancer Surv. 25 (1995) 233-275
4. Giese A., and Westphal M. Glioma invasion in the central nervous system. Neurosurgery 39 (1996) 235-250
5. Kleihues P., Lubbe J., Watanabe K., von Ammon K., and Ohgaki H. Genetic alterations associated with glioma progression. Verh. Dtsch. Ges. Pathol. 78 (1994) 43-47
6. Jansen M., de Witt Hamer P.C., Witmer A.N., Troost D., and van Noorden C.J. Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. Brain Res. Brain Res. Rev. 45 (2004) 143-163
7. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
8. Kang X., Xiao X., Harata M., Bai Y., Nakazaki Y., Soda Y., Kurita R., Tanaka T., Komine F., Izawa K., Kunisaki R., Setoyama M., Nishimori H., Natsume A., Sunamura M., Lozonshi L., Saitoh I., Tokino T., Asano S., Nakamura Y., and Tani K. Antiangiogenic activity of BAI1 in vivo: implications for gene therapy of human glioblastomas. Cancer Gene Ther. 13 (2006) 385-392
9. Perri S.R., Nalbantoglu J., Annabi B., Koty Z., Lejeune L., Francois M., Di Falco M.R., Beliveau R., and Galipeau J. Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression. Cancer Res. 65 (2005) 8359-8365
10. Purow B., and Fine H.A. Progress report on the potential of angiogenesis inhibitors for neuro-oncology. Cancer Invest. 22 (2004) 577-587
11. Dirkx A.E., oude Egbrink M.G., Castermans K., van der Schaft D.W., Thijssen V.L., Dings R.P., Kwee L., Mayo K.H., Wagstaff J., Bouma-ter Steege J.C., and Griffioen A.W. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 20 (2006) 621-630
12. te Velde E.A., Vogten J.M., Gebbink M.F., van Gorp J.M., Voest E.E., and Borel Rinkes I.H. Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. Brit. J. Surg. 89 (2002) 1302-1309
13. Gasparini G., Longo R., Fanelli M., and Teicher B.A. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J. Clin. Oncol. 23 (2005) 1295-1311
14. Patthy L. Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modules. Cell 41 (1985) 657-663
15. Brockmann M.A., Papadimitriou A., Brandt M., Fillbrandt R., Westphal M., and Lamszus K. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin. Cancer Res. 9 (2003) 4578-4585
16. Kim J.S., Chang J.H., Yu H.K., Ahn J.H., Yum J.S., Lee S.K., Jung K.H., Park D.H., Yoon Y., Byun S.M., and Chung S.I. Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a). J. Biol. Chem. 278 (2003) 29000-29008
17. Kim K.S., Hong Y.K., Joe Y.A., Lee Y., Shin J.Y., Park H.E., Lee I.H., Lee S.Y., Kang D.K., Chang S.I., and Chung S.I. Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells. J. Biol. Chem. 278 (2003) 11449-11456
18. Kim K.S., Hong Y.K., Lee Y., Shin J.Y., Chang S.I., Chung S.I., and Joe Y.A. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain. Exp. Mol. Med. 35 (2003) 578-585
19. Kim C.K., Hong S.H., Joe Y.A., Shim B.S., Lee S.K., and Hong Y.K. The recombinant kringle domain of urokinase plasminogen activator inhibits in vivo malignant glioma growth. Cancer Sci. 98 (2007) 253-258
20. Husain S.S., Szabo I.L., and Tamawski A.S. NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. Am. J. Gastroenterol. 97 (2002) 542-553
21. Liu X.H., Kirschenbaum A., Yao S., Lee R., Holland J.F., and Levine A.C. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J. Urol. 164 (2000) 820-825
22. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metast. Rev. 19 (2000) 19-27
23. Gately S., and Li W.W. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin. Oncol. 31 (2004) 2-11
24. Nam D.H., Park K., Park C., Im Y.H., Kim M.H., Lee S., Hong S.C., Shin H.J., Kim J.H., Eoh W., and McDonnell T.J. Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib. Oncol. Rep. 11 (2004) 263-268
25. Leahy K.M., Ornberg R.L., Wang Y., Zweifel B.S., Koki A.T., and Masferrer J.L. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 62 (2002) 625-631
26. Chen Z., Zhang X., Li M., Wang Z., Wieand H.S., Grandis J.R., and Shin D.M. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, An efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin. Cancer Res. 10 (2004) 5930-5939
27. Jaffe E.A., Nachman R.L., Becker C.G., and Minick C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 52 (1973) 2745-2756
28. Kim H.K., Hong Y.K., Park H.E., Hong S.H., and Joe Y.A. Secretory production of recombinant urokinase kringle domain in Pichia pastoris. J. Microbiol. Biotechnol. 13 (2003) 591-597
29. Joe Y.A., Hong Y.K., Chung D.S., Yang Y.J., Kang J.K., Lee Y.S., Chang S.I., You W.K., Lee H., and Chung S.I. Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3. Int. J. Cancer 82 (1999) 694-699
30. Kim H.K., Oh D.S., Lee S.B., Ha J.M., and Joe Y.A. Antimigratory effect of TK1-2 is mediated in part by interfering with integrin alpha2beta1. Mol. Cancer Ther. 7 (2008) 2133-2141
31. Goldbrunner R.H., Bendszus M., and Tonn J.C. Models for angiogenesis in gliomas. Cancer Treat Res. 117 (2004) 115-135
32. Choy H., and Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?. J. Natl. Cancer Inst. 95 (2003) 1440-1452
33. Basu G.D., Pathangey L.B., Tinder T.L., Lagioia M., Gendler S.J., and Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol. Cancer Res. 2 (2004) 632-642
34. Niederberger E., Manderscheid C., Grosch S., Schmidt H., Ehnert C., and Geisslinger G. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem. Pharmacol. 68 (2004) 341-350
35. Lin H.P., Kulp S.K., Tseng P.H., Yang Y.T., Yang C.C., Chen C.S., and Chen C.S. Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms. Mol. Cancer Ther. 3 (2004) 1671-1680
36. Ragel B.T., Jensen R.L., Gillespie D.L., Prescott S.M., and Couldwell W.T. Celecoxib inhibits meningioma tumor growth in a mouse xenograft model. Cancer 109 (2007) 588-597
37. Ahn J.H., Kim J.S., Yu H.K., Lee H.J., and Yoon Y. A truncated kringle domain of human apolipoprotein(a) inhibits the activation of extracellular signal-regulated kinase 1 and 2 through a tyrosine phosphatase-dependent pathway. J. Biol. Chem. 279 (2004) 21808-21814
38. Nakabayashi M., Morishita R., Nakagami H., Kuba K., Matsumoto K., Nakamura T., Tano Y., and Kaneda Y. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model. Diabetologia 46 (2003) 115-123
39. Plate K.H., Breier G., Weich H.A., and Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359 (1992) 845-848
40. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9 (2003) 669-676
41. Kang K.B., Wang T.T., Woon C.T., Cheah E.S., Moore X.L., Zhu C., and Wong M.C. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. Int. J. Radiat. Oncol. Biol. Phys. 67 (2007) 888-896
42. Kim E.O.H.K., Hong S.H., Kim C.K., Hong Y.K., and Joe Y.A. Integrin alphavbeta3 is not significantly implicated in the anti-migratory effect of anti-angiogenic urokinase kringle domain. Oncol. Rep. 20 (2008) 631-636